Lilly’s Mounjaro overtakes Keytruda
Digest more
Merck (NYSE:MRK | MRK Price Prediction) delivered its fourth consecutive earnings beat, but shares slipped on the earnings ...
Merck narrowed its 2026 sales guidance and hiked its adjusted profit outlook.
Merck topped first-quarter sales estimates as Winrevair and injectable Keytruda Qlex helped support revenue growth.
A triplet regimen comprising Merck’s Welireg and PD-1 blockbuster Keytruda and Eisai’s Lenvima flopped in a Phase 3 renal cell carcinoma trial.
Merck’s MRK strong foothold in the oncology space is propelled by its biggest revenue driver, Keytruda. The blockbuster PD-L1 inhibitor alone accounted for more than 50% of the company’s ...
In late April 2026, Merck reported first‑quarter results that beat expectations, slightly raised full‑year 2026 sales ...
By Deena Beasley and Mariam Sunny April 30 (Reuters) - Merck on Thursday beat first-quarter sales expectations on strong ...
Eli Lilly’s diabetes and obesity drug Mounjaro has overtaken Merck’s cancer therapy Keytruda to become the world’s ...
Merck & Co., Inc. remains the largest U.S. pharma company in 2025, driven by oncology and Keytruda, despite looming patent expiration risks. Keytruda accounts for over half of MRK's ...
Merck & Co.’s Keytruda has become the first immunotherapy approved by the FDA to be used around surgery to treat resectable locally advanced head and neck cancer. But the breakthrough approval ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results